Your session is about to expire
← Back to Search
Sound Therapy
Sound and Music Therapy for Mild Cognitive Impairment
N/A
Waitlist Available
Led By JUNXIN LI, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Community-dwelling with amnesia or mild cognitive impairment
Be older than 18 years old
Must not have
Known diagnosis of schizophrenia or Parkinson's disease
Severe hearing impairment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and immediately after the 4-week intervention
Awards & highlights
No Placebo-Only Group
Summary
This trial will compare the effects of 40 Hz sound, music, and a combination of the two on cognitive function in older adults with mild cognitive impairment.
Who is the study for?
This trial is for older adults who have mild cognitive impairment but can still take care of themselves. They shouldn't have dementia, schizophrenia, Parkinson's disease, severe hearing loss, or any serious medical/psychiatric issues that would stop them from following the study.
What is being tested?
The study tests three things: music at a specific frequency (40 Hz), just the sound at this frequency without music, and whatever music the participant likes best. The goal is to see if these sounds improve brain function in those with mild cognitive issues.
What are the potential side effects?
Since this trial involves listening to sounds or music, side effects might include discomfort due to volume or frequency of sound for those with sensitive hearing but are generally expected to be minimal.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I live at home and have memory loss or mild thinking problems.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with schizophrenia or Parkinson's disease.
Select...
I have severe hearing loss.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and immediately after the 4-week intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and immediately after the 4-week intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Cognitive function
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: 3Experimental Treatment3 Interventions
this group will be exposed to condition C first, then A, and B
Group II: 2Experimental Treatment3 Interventions
this group will be exposed to condition B first, then C, and A
Group III: 1Experimental Treatment3 Interventions
this group will be exposed to condition A first, then B, and C
Find a Location
Who is running the clinical trial?
Johns Hopkins UniversityLead Sponsor
2,321 Previous Clinical Trials
14,873,911 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,782 Previous Clinical Trials
28,184,063 Total Patients Enrolled
JUNXIN LI, PhDPrincipal InvestigatorJohns Hopkins University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with schizophrenia or Parkinson's disease.I have severe hearing loss.I live at home and have memory loss or mild thinking problems.My organs are working well.
Research Study Groups:
This trial has the following groups:- Group 1: 1
- Group 2: 2
- Group 3: 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger